CD8A and melanoma: (33) further corroborated these findings by covalently linking TLR2/6 and TLR7/8 agonists to pathogen-like nanoassemblies (MTAs), which remarkably enhanced CD8+ T cell mediated antitumor responses with low off-target toxicity in murine melanoma; however, this study did not report if the TLR stimulus was acting on APCs or CD8+ T cells (33).